Placebo News and Research

RSS

Depression drug Cymbalta eases chronic back pain

A drug used to treat depression has been found to also be effective in reducing chronic low back pain.

28 Aug 2008

Gleevec receives FDA priority review for gastrointestinal stromal tumors after surgery

Novartis has announced that Gleevec (imatinib mesylate) tablets, (known as Glivec (imatinib) outside the US, Canada and Israel), has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors (GIST).

27 Aug 2008

Olive leaf extract (EFLA943) helps tackle high blood pressure and cholesterol

Taking 1000mg of a specific olive leaf extract (EFLA943) can lower cholesterol and lower blood pressure in patients with mild hypertension (high blood pressure).

26 Aug 2008

Medication slows progression of myopia in children

Daily treatment with a medication called pirenzepine can slow the rate of progressive myopia, or nearsightedness, in children, reports a study in the August issue of the Journal of AAPOS (American Association for Pediatric Ophthalmology and Strabismus).

26 Aug 2008

Good tidings for women on HRT

For many women struggling to deal with the symptoms of the menopause, the latest research on hormone replacement therapy (HRT) bears good tidings.

25 Aug 2008

Cymbalta approved in Europe for generalised anxiety disorder

Eli Lilly and Co and Boehringer Ingelheim have announced that the European Commission has approved the use of Cymbalta (duloxetine) for the treatment of Generalised Anxiety Disorder (GAD).

24 Aug 2008

Addiction drug Vigabatrin proves successful in animal weight loss study

Vigabatrin, a medication proposed as a potential treatment for drug addiction by scientists at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory, also leads to rapid weight loss and reduced food intake according to a new animal study from the same research group.

20 Aug 2008

Vitamin B supplements offer no protection from heart disease

According to recent research vitamin B or folic acid supplements do not prevent death in patients with heart disease.

20 Aug 2008

Alexander Technique shows long-term benefit for low back pain

A major study - one of the first of its kind - has found significant evidence that the Alexander Technique can provide long-term benefit for people suffering from chronic or recurrent low back pain. The study by researchers at the Universities of Bristol and Southampton is published today in the BMJ.

19 Aug 2008

FDA approves tetrabenazine for Huntington's disease

The U.S. Food and Drug Administration has approved tetrabenazine, the first drug approved for use in the United States to treat Huntington's disease, a fatal, inherited neurodegenerative disorder for which there is no cure. The action comes about eight months after an advisory panel unanimously voted to advise FDA to make the medication available to treat the disease.

17 Aug 2008

Isis Pharmaceuticals trials C-reactive protein drug

Isis Pharmaceuticals, Inc. announced today it has initiated a Phase 1 study of ISIS 353512, an antisense drug that inhibits the production of C-reactive protein (CRP). CRP levels are frequently elevated in patients with a variety of diseases including cardiovascular disease, Crohn's disease, rheumatoid arthritis and end-stage renal disease.

13 Aug 2008

New drug targets main culprit in common colds

The Melbourne drug company Biota has announced trials of a drug to treat the human rhinovirus (HRV) which is the main culprit in the common cold.

12 Aug 2008

Medicinal cannabis effective for neuropathic pain in HIV

In a double-blind, placebo-controlled clinical trial to assess the impact of smoked medical cannabis, or marijuana, on the neuropathic pain associated with HIV, researchers at the University of California, San Diego School of Medicine found that reported pain relief was greater with cannabis than with a placebo.

6 Aug 2008

Bionor Immuno trials new innovative therapeutic immunization designed to help existing HIV and AIDS patients

Bionor Immuno today announced that it has advanced its efforts to develop the first HIV therapeutic immunization with the dosing of patients in a global Phase 2b clinical trial of the company's lead candidate (Vacc-4x).

4 Aug 2008

Vitamin C injections slow tumor growth in mice

High-dose injections of vitamin C, also known as ascorbate or ascorbic acid, reduced tumor weight and growth rate by about 50 percent in mouse models of brain, ovarian, and pancreatic cancers, researchers from the National Institutes of Health (NIH) report in the August 5, 2008, issue of the Proceedings of the National Academy of Sciences.

4 Aug 2008

Garlic supplements may help control high blood pressure

According to a new review of relevant research, garlic supplements may be as effective at lowering blood pressure as some hypertension drugs.

4 Aug 2008

Epilepsy drug gabapentin may reduce insomnia in recovering alcoholics

It's a Catch-22 of the highest order. People with alcohol problems often use alcohol to get to sleep -- but it actually keeps them from getting good-quality sleep all night long.

4 Aug 2008

Growth hormone reduces abdominal fat, cardiovascular risk in HIV patients on antiviral therapy

Low-dose growth hormone treatment reduced abdominal fat deposits and improved blood pressure and triglyceride levels in a group of patients with HIV lipodystrophy, a condition involving the redistribution of fat and other metabolic changes in patients receiving combination drug therapy for HIV infection.

3 Aug 2008

Fatal flaws in the way new drugs are tested and marketed

Americans are likely to be exposed to unacceptable side effects of FDA-approved drugs such as Vioxx in the future because of fatal flaws in the way new drugs are tested and marketed, according to research to be presented at the annual meeting of the American Sociological Association (ASA).

3 Aug 2008

New studies examine use of the nucleoside polymerase inhibitor, R1626, to the standard therapy for hepatitis C

Two new studies examine the use of the nucleoside polymerase inhibitor, R1626, to the standard therapy for hepatitis C. The reports appear in the August issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD).

31 Jul 2008